Robert P. Whitehead - Concepedia

Author

Robert P. Whitehead

SWOG Cancer Research Network

Also Known As

R P Whitehead, R. P. Whitehead, R. WHITEHEAD, Robert P Whitehead, Robert P. Whitehead, Robert Whitehead

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

SWOG Cancer Research Network Cancer Research And Biostatistics University of Arizona Wayne State University The University of Texas Medical Branch at Galveston

About

Robert P. Whitehead is an author at SWOG Cancer Research Network specializing in oncology, cancer research, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	491
2	Immunology	5	5	156
3	Pathology	5	5	280
4	Health Sciences	3	3	70
5	Diagnostic Sciences	1	1	50

Robert P. Whitehead

Publications

976

Citations

H-Index

Page 1

	Year	Citations
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors Jon Chung, Ninad Dewal, Ethan Sokol, JCO Precision Oncology	2019	160
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study John S. Macdonald, Sheryl McCoy, Robert P. Whitehead, Investigational New Drugs Swog 9924Pancreatic CancerGastrointestinal OncologyMedicinePharmacology	2005	148
Phase II Trial of High-Dose Intermittent Interleukin-2 in Metastatic Renal Cell Carcinoma: A Southwest Oncology Group Study Ronald M. Bukowski, Phyllis J. Goodman, E. David Crawford, JNCI Journal of the National Cancer Institute	1990	98
Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727) Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Cancer	2014	92
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) Robert P. Whitehead, Cathryn Rankin, Paulo M. Hoff, Investigational New Drugs Phase Ii TrialGastrointestinal OncologyMedicinePharmacologyColorectal Cancer	2008	82
A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study Robert P. Whitehead, Sheryl McCoy, Saul E. Rivkin, Investigational New Drugs OncologyPhase Ii TrialGastrointestinal OncologyMedicinePharmacotherapy	2006	71
Phase II Studies of Recombinant Human Tumor Necrosis Factor Alpha in Patients with Malignant Disease: A Summary of the Southwest Oncology Group Experience Evan M. Hersh, Barbara Metch, Franco M. Muggia, Journal of Immunotherapy	1991	66
Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Robert P. Whitehead, D Ward, Lauren Hemingway, PubMed UrologyGenitourinary CancerMedicineImmunologyImmune Checkpoint Inhibitor	1990	57
Phase II Study of Intravenous Bolus Recombinant Interleukin-2 in Advanced Malignant Melanoma: Southwest Oncology Group Study Robert P. Whitehead, Kenneth J. Kopecky, Michael K. Samson, JNCI Journal of the National Cancer Institute ImmunologyPhase Ii StudyImmunotherapeuticsImmunotherapyOncology	1991	50
Phase II Trial of Recombinant Human Interleukin-4 in Patients with Disseminated Malignant Melanoma Robert P. Whitehead, Joseph M. Unger, J. Wendall Goodwin, Journal of Immunotherapy	1998	46

Page 1